---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059780"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2026-05-13T11:23:09+00:00"
generated_at: "2026-05-13T11:25:08.272371+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Milestone Q1 2026 net loss $26.1M; CARDAMYST launch yields $0.2M revenue, 600 scripts

## Summary
- Product revenue of $0.2M from first quarter of CARDAMYST launch; no prior-year revenue.
- Net loss $26.1M ($0.20 per share) vs $20.8M ($0.31) a year ago; cash $184.2M, runway into H2 2027.
- ~600 scripts filled for 560 PSVT patients; ~400 unique prescribers as of April.
- Express Scripts national formulary coverage effective March 27, 2026; >25% of commercially insured lives covered.
- Phase 3 AFib-RVR trial initiated; first patient enrollment expected H2 2026.

## SEC filing metadata
- accession: 0001104659-26-059780
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2026-05-13T11:23:09+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/0001104659-26-059780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/tm2614433d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059780
- JSON: https://secwatch.observer/filing/0001104659-26-059780.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059780.txt

## Key facts
- Earnings Releases
  Milestone Pharmaceuticals Inc. reported the first quarter ended March 31, 2026 results: revenue $0.2 million.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $0.2 million
  - Result: reported results
  source text: into the second half of 2027, including expenses expected in connection with the initiation of the Phase 3 trial in AFib-RVR, as described above. · Product revenues were $0.2 million during the three months ended March 31, 2026. There was no product revenue during the three months ended March 31, 2025. · Research and development expense for the first
  evidence_url: https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/0001104659-26-059780-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.